TABLE 3.
HCC‐related and overall mortality per 100,000 screened patients according to HCC annual incidence, showing 6‐month US compared to no surveillance
| Annual HCC incidence | HCC‐related deaths | Overall deaths | Death attributable to HCC (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No surveillance (ref.) | 6‐M US | Abs. diff. | Rel. diff. | No surveillance (ref.) | 6‐M US | Abs. Diff. | Rel. Diff. | No surveillance (ref.) | 6‐M US | |
| 0.2% | 712 | 431 | −281 | −39.5% | 19,203 | 19,016 | −187 | −1.0% | 3.7% | 2.3% |
| 0.4% | 1430 | 865 | −565 | −39.5% | 19,905 | 19,531 | −374 | −1.9% | 7.2% | 4.4% |
| 1.5% | 5205 | 3146 | −2059 | −39.6% | 23,595 | 22,239 | −1356 | −5.7% | 22.1% | 14.1% |
Note: Baseline case scenario relies on a tumor doubling time of 90 days.
Abbreviations: Abs., absolute; diff., difference; HCC, hepatocellular carcinoma; M, month; ref., reference; US, ultrasound.